Meaningful survival in lung cancer patients

Sakkaraiappan Ramalingam, Chandra P. Belani

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Lung cancer is diagnosed at an advanced stage in a majority of patients. Recent advances made in the treatment of lung cancer have resulted in a prolongation in survival and an improvement in quality of life. The majority of lung cancer patients experience multiple symptoms, which result from both the cancer and its treatment. Fatigue and anemia cause significant morbidity and impaired quality of life among patients with lung cancer. They also contribute to a suboptimal response to treatment modalities such as radiation, decreased performance status, and poor patient compliance with treatment. The impact of anemia is frequently under-recognized. Improvements in survival made with multimodality therapy can only be meaningful when combined with interventions to improve symptoms and overall quality of life. Prompt recognition of these problems and early intervention are an integral part of cancer therapy. In this review, we discuss the impact of anemia and the treatment options that could contribute to a truly meaningful survival in lung cancer patients.

Original languageEnglish (US)
Pages (from-to)125-131
Number of pages7
JournalSeminars in oncology
Volume29
Issue number1 SUPPL. 4
DOIs
StatePublished - Jan 1 2002

Fingerprint

Lung Neoplasms
Survival
Anemia
Quality of Life
Therapeutics
Patient Compliance
Fatigue
Neoplasms
Radiation
Morbidity

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Ramalingam, Sakkaraiappan ; Belani, Chandra P. / Meaningful survival in lung cancer patients. In: Seminars in oncology. 2002 ; Vol. 29, No. 1 SUPPL. 4. pp. 125-131.
@article{95070a94351447ab8280a0cd72da614d,
title = "Meaningful survival in lung cancer patients",
abstract = "Lung cancer is diagnosed at an advanced stage in a majority of patients. Recent advances made in the treatment of lung cancer have resulted in a prolongation in survival and an improvement in quality of life. The majority of lung cancer patients experience multiple symptoms, which result from both the cancer and its treatment. Fatigue and anemia cause significant morbidity and impaired quality of life among patients with lung cancer. They also contribute to a suboptimal response to treatment modalities such as radiation, decreased performance status, and poor patient compliance with treatment. The impact of anemia is frequently under-recognized. Improvements in survival made with multimodality therapy can only be meaningful when combined with interventions to improve symptoms and overall quality of life. Prompt recognition of these problems and early intervention are an integral part of cancer therapy. In this review, we discuss the impact of anemia and the treatment options that could contribute to a truly meaningful survival in lung cancer patients.",
author = "Sakkaraiappan Ramalingam and Belani, {Chandra P.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1053/sonc.2002.31533",
language = "English (US)",
volume = "29",
pages = "125--131",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 4",

}

Meaningful survival in lung cancer patients. / Ramalingam, Sakkaraiappan; Belani, Chandra P.

In: Seminars in oncology, Vol. 29, No. 1 SUPPL. 4, 01.01.2002, p. 125-131.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Meaningful survival in lung cancer patients

AU - Ramalingam, Sakkaraiappan

AU - Belani, Chandra P.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Lung cancer is diagnosed at an advanced stage in a majority of patients. Recent advances made in the treatment of lung cancer have resulted in a prolongation in survival and an improvement in quality of life. The majority of lung cancer patients experience multiple symptoms, which result from both the cancer and its treatment. Fatigue and anemia cause significant morbidity and impaired quality of life among patients with lung cancer. They also contribute to a suboptimal response to treatment modalities such as radiation, decreased performance status, and poor patient compliance with treatment. The impact of anemia is frequently under-recognized. Improvements in survival made with multimodality therapy can only be meaningful when combined with interventions to improve symptoms and overall quality of life. Prompt recognition of these problems and early intervention are an integral part of cancer therapy. In this review, we discuss the impact of anemia and the treatment options that could contribute to a truly meaningful survival in lung cancer patients.

AB - Lung cancer is diagnosed at an advanced stage in a majority of patients. Recent advances made in the treatment of lung cancer have resulted in a prolongation in survival and an improvement in quality of life. The majority of lung cancer patients experience multiple symptoms, which result from both the cancer and its treatment. Fatigue and anemia cause significant morbidity and impaired quality of life among patients with lung cancer. They also contribute to a suboptimal response to treatment modalities such as radiation, decreased performance status, and poor patient compliance with treatment. The impact of anemia is frequently under-recognized. Improvements in survival made with multimodality therapy can only be meaningful when combined with interventions to improve symptoms and overall quality of life. Prompt recognition of these problems and early intervention are an integral part of cancer therapy. In this review, we discuss the impact of anemia and the treatment options that could contribute to a truly meaningful survival in lung cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0036124474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036124474&partnerID=8YFLogxK

U2 - 10.1053/sonc.2002.31533

DO - 10.1053/sonc.2002.31533

M3 - Article

C2 - 11894023

AN - SCOPUS:0036124474

VL - 29

SP - 125

EP - 131

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 4

ER -